GNPX - Genprex, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9360
-0.0277 (-2.87%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close0.9637
Open0.9800
Bid0.9000 x 900
Ask1.3000 x 800
Day's Range0.9301 - 0.9800
52 Week Range0.6410 - 2.7500
Volume69,457
Avg. Volume40,648
Market Cap14.829M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector” and produced by NetworkNewsWire (“NNW”). With significant milestones being met, Genprex Inc. (GNPX) is pressing forward with its strategy objectives to reprogram the course of cancer. The company plans on continuing to conduct ongoing and new clinical trials as well as pursue strategic partnerships with organizations whose missions align with its own.

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements

    NEW YORK, Aug. 22, 2019 -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire

    Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference

    Genprex, Inc. , a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019.

  • Business Wire

    Genprex Demonstrates Growth and Expansion Through Recent Achievements

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex™ immunogene therapy, to commercialization. “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initatives,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex.

  • Business Wire

    Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018. Genprex’s initial product candidate, Oncoprex™ consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge.

  • Business Wire

    Genprex Begins Next Phase of Drug Branding Program

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it has initiated the first phase of branding its lead drug candidate, Oncoprex™ immunogene therapy, and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

  • Business Wire

    Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer

    Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). In July 2018, the company entered a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to fund a research study entitled, “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy.” The TUSC2 gene is the active agent in Genprex’s Oncoprex immunogene therapy.

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment

    Preliminary results show that Oncoprex has the potential to become an effective add-on therapy for the treatment of deadly non-small cell lung cancer. Genprex Inc. (GNPX) plans to expand the current erlotinib-Oncoprex trial to multiple research centers and conduct more new trials. If Phase II results are as positive as preliminary indications, it could spark a rally in the shares and possibly even lure a large biotechnology or pharma company to sign a high-value partnership with Genprex.

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs  

    NEW YORK, May 30, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire

    Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Genprex will be among the 30+ presentations by listed and private biotechnology companies at the event.

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies

    Gene therapies, the promising treatments pursued by companies such as Genprex Inc. (GNPX), are based on turning [the] problem [of cell mutation] on its head. Once in place, successful gene therapies replace damaged or missing code and help the body cure itself. Creating these treatments is challenging work, and the companies that excel are innovators with the ability to try new approaches.

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment

    NEW YORK, May 08, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire

    Genprex Retains Addison Whitney for Drug Nomenclature Branding

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney. Addison Whitney, a Syneos Health company, will draw from its 28-year history to oversee the proprietary and non-proprietary drug naming process for Genprex’s lead drug candidate, currently known as Oncoprex™ immunogene therapy, for non-small cell lung cancer. Oncoprex immunogene therapy has shown promise in targeting and treating non-small cell lung cancer (NCSLC) through its proprietary technology platform, which transports cancer-fighting genes to cancerous cells by encapsulating the genes into nanoscale hollow spheres, called nanovesicles, which are then administered intravenously.

  • Newsfile

    Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer

    New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, "Potential Blockbuster Gene Therapy Programs to Watch in 2019."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMsTo read the full editorial, visit: http://nnw.fm/YC9iqGenprex already has over 30 issued patents for its platform technologies. The company's promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in ...

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable

    The company’s promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in combination with another cancer drug, Tarceva, and pre-clinical research of the combination of Oncoprex immunogene therapy with immunotherapies. Gene therapy programs may be on the cusp of curing the incurable, and the companies that deliver these medical miracles are in an ideal position to reap a bonanza of recognition and rewards. Given the promise of Genprex’s pipeline of cancer killers with global blockbuster potential, the company certainly appears to be one to watch.

  • Newsfile

    Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies

    New York, New York--(Newsfile Corp. - April 11, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Potential Blockbuster Gene Therapy Programs to Watch in 2019," visit: http://nnw.fm/YC9iqPerhaps no other disease strikes as much dread and fear as cancer. Many successful treatments are available today that didn't exist just ...

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment

    NEW YORK, April 11, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Business Wire

    Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

    TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade

  • Business Wire

    Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission. “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex™ immunogene therapy for non-small cell lung cancer,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “I’m pleased with our progress and am excited to continue development of our gene therapies for cancer into 2019 and beyond.

  • Newsfile

    Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment

    New York, New York--(Newsfile Corp. - March 29, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio publication titled, "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/XRt4dTo read the full editorial, visit: http://nnw.fm/tB7LiA multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: ...

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy

    A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (GNPX) (GNPX Profile) is working to bring its potentially life-changing immunogene therapy, Oncoprex, to market. Genprex already has 30 issued patents for its platform technologies and gene therapies.

  • GlobeNewswire

    Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments

    NEW YORK, March 28, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.

  • Newsfile

    Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy

    New York, New York--(Newsfile Corp. - March 28, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy," visit: http://nnw.fm/l3DkVGenprex is on the cusp of potentially delivering life-changing therapeutics for cancer patients by utilizing the company's novel proprietary technology platform. ...

  • GlobeNewswire

    Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire

    NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer. NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC). The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer.

  • Newsfile

    NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy

    New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NASD: GNPX).To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cXTo read the full editorial, visit: http://nnw.fm/Y0ZqHThis evidence of the faith of the markets has helped boost stock values for a range of gene therapy companies, with some seeing triple digit growth. But these companies don't need to be the ...